Soota D, Saravanan B, Mann R, Kharbanda T, Notani D
EMBO J. 2024; 43(21):5186-5210.
PMID: 39284910
PMC: 11535219.
DOI: 10.1038/s44318-024-00225-y.
Helsen C, Rocca M, Nguyen T, Eerlings R, Lee X, De Block S
Protein Sci. 2023; 32(4):e4599.
PMID: 36806291
PMC: 10019450.
DOI: 10.1002/pro.4599.
Helsen C, Nguyen T, Vercruysse T, Wouters S, Daelemans D, Voet A
Int J Mol Sci. 2022; 23(3).
PMID: 35163481
PMC: 8836279.
DOI: 10.3390/ijms23031557.
Arnold F, Merry D
Neurotherapeutics. 2019; 16(4):928-947.
PMID: 31686397
PMC: 6985201.
DOI: 10.1007/s13311-019-00790-9.
Bai S, Zhang B, Dong Y
Asian J Androl. 2018; 21(3):249-252.
PMID: 29900882
PMC: 6498725.
DOI: 10.4103/aja.aja_37_18.
Comparing the rules of engagement of androgen and glucocorticoid receptors.
Claessens F, Joniau S, Helsen C
Cell Mol Life Sci. 2017; 74(12):2217-2228.
PMID: 28168446
PMC: 5425506.
DOI: 10.1007/s00018-017-2467-3.
Polyglutamine androgen receptor-mediated neuromuscular disease.
Giorgetti E, Lieberman A
Cell Mol Life Sci. 2016; 73(21):3991-9.
PMID: 27188284
PMC: 5045769.
DOI: 10.1007/s00018-016-2275-1.
Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS).
Chiu C, Patsch K, Cutrale F, Soundararajan A, Agus D, Fraser S
Sci Rep. 2016; 6:22435.
PMID: 26936218
PMC: 4776155.
DOI: 10.1038/srep22435.
Insights into Chemoresistance of Prostate Cancer.
Zhang W, Meng Y, Liu N, Wen X, Yang T
Int J Biol Sci. 2015; 11(10):1160-70.
PMID: 26327810
PMC: 4551752.
DOI: 10.7150/ijbs.11439.
N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy.
Martin S, Banuelos C, Sadar M, Kyprianou N
Mol Oncol. 2014; .
PMID: 25432105
PMC: 4433435.
DOI: 10.1016/j.molonc.2014.10.014.
Emerging mechanisms of enzalutamide resistance in prostate cancer.
Claessens F, Helsen C, Prekovic S, Van den Broeck T, Spans L, van Poppel H
Nat Rev Urol. 2014; 11(12):712-6.
PMID: 25224448
DOI: 10.1038/nrurol.2014.243.
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
Kahn B, Collazo J, Kyprianou N
Int J Biol Sci. 2014; 10(6):588-95.
PMID: 24948871
PMC: 4062951.
DOI: 10.7150/ijbs.8671.
Constitutive activity of the androgen receptor.
Chan S, Dehm S
Adv Pharmacol. 2014; 70:327-66.
PMID: 24931201
PMC: 4277179.
DOI: 10.1016/B978-0-12-417197-8.00011-0.
Minireview: The versatile roles of lysine deacetylases in steroid receptor signaling.
Kadiyala V, Smith C
Mol Endocrinol. 2014; 28(5):607-21.
PMID: 24645680
PMC: 5414849.
DOI: 10.1210/me.2014-1002.
Androgen receptor splice variants determine taxane sensitivity in prostate cancer.
Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella R
Cancer Res. 2014; 74(8):2270-2282.
PMID: 24556717
PMC: 4012562.
DOI: 10.1158/0008-5472.CAN-13-2876.
Allosteric conversation in the androgen receptor ligand-binding domain surfaces.
Grosdidier S, Carbo L, Buzon V, Brooke G, Nguyen P, Baxter J
Mol Endocrinol. 2012; 26(7):1078-90.
PMID: 22653923
PMC: 5416996.
DOI: 10.1210/me.2011-1281.
Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.
Chan S, Li Y, Dehm S
J Biol Chem. 2012; 287(23):19736-49.
PMID: 22532567
PMC: 3366007.
DOI: 10.1074/jbc.M112.352930.
Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation.
Kumar R, McEwan I
Endocr Rev. 2012; 33(2):271-99.
PMID: 22433123
PMC: 3596562.
DOI: 10.1210/er.2011-1033.
The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity.
Hay C, McEwan I
PLoS One. 2012; 7(3):e32514.
PMID: 22403669
PMC: 3293822.
DOI: 10.1371/journal.pone.0032514.
General molecular biology and architecture of nuclear receptors.
Pawlak M, Lefebvre P, Staels B
Curr Top Med Chem. 2012; 12(6):486-504.
PMID: 22242852
PMC: 3637177.
DOI: 10.2174/156802612799436641.